Kurs & Likviditet
|Lista||First North Stockholm|
|2021-10-06||Extra Bolagsstämma 2021|
|2021-05-27||Ordinarie utdelning SCOL 0.00 SEK|
|2020-05-28||Ordinarie utdelning SCOL 0.00 SEK|
|2019-06-11||Extra Bolagsstämma 2019|
|2019-05-31||Ordinarie utdelning SCOL 0.00 SEK|
On Thursday 1 October 2020, the Extraordinary General Meeting of Scandion Oncology A/S was held. Below follows a summary of the established decisions. All decisions were taken with the required majority and in accordance with the notice of the extraordinary general meeting.
Establishment of an incentive program by issuance of warrants to the board of directors
The general meeting decided that Scandion Oncology A/S will establish an incentive program by issuance of up to 214,338 warrants to the board of directors of Scandion Oncology A/S to be distributed as follows:
(i) Chairman: 71,447 warrants
(ii) Deputy chairman: 47,631 warrants
(iii) Other board members: 23,815 per board member (excluding the board member appointed by the employees).
Establishment of an incentive program by issuance of warrants to the CEO and the employees
The general meeting decided that Scandion Oncology A/S will establish an incentive program by issuance of up to 1,286,026 warrants to the CEO and the employee of Scandion Oncology A/S to be distributed by the board of directors in accordance with the following guidelines:
(i) CEO: 1,071,688 warrants
(ii) Employees: Not more than 70,000 warrants per employee (214,338 warrants in total).
For further information regarding Scandion Oncology A/S, please contact:
Bo Rode Hansen, CEO
Phone: + 45 28 34 08 71
Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology A/S is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology A/S was listed on Spotlight Stock Market, Sweden in November 2018.